TER regimen with ranibizumab improves retinal anatomy over 24 months in DME
Significantly improvements in visual acuity and retinal anatomical structure over the course of 2 years were seen in patients with diabetic macular edema (DME) following a treat and extend regimen (TER) without loading dose under ranibizumab, according to a study.
In this retrospective study, 118 eyes of 87 patients were analyzed for 24 months after the initiation of TER.
During the first and second year, a mean of 9.742.13 injections and 7.632.29 injections, respectively, were applied. From baseline to month 12 and 24, there were significant gains of BCVA and reductions in central retinal thickness. From a baseline of15.3%, the percentage of eyes with an intact inner-/outer segment (IS/OS) junction increased to 42.1% after 2 years. Eyes at baseline that had an intact IS/OS junction increased the probability of having a dry retina after 12 months by 79.3% and after 24 months by 88.1%, and those with less IS/OS disruption baseline predicted longer maximum recurrence-free treatment intervals at 2 years and better BCVA at 1 year.
Bigger intraretinal cysts at baseline was associated with more IS/OS disruption at 2 years. Patients who were younger and those who had lower BCVA at baseline were linked with a higher BCVA gain at 24 months
Reference
Giannakaki-Zimmermann H, Behrndt A, Hoffmann L, et al. Predictors for 2-year functional and morphological outcomes of a treat and extend regimen with ranibizumab in patients with diabetic macular edema. Ophthalmic Res. 2021; https://doi.org/10.1159/000514721.
